Mode
Text Size
Log in / Sign up

Review of solitary plasmacytoma radiotherapy outcomes in Indian tertiary careRare Bone Tumor Treatment Shows Long-Term Success with Radiotherapy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that this retrospective audit shows long median PFS and TTNT after radiotherapy for solitary plasmacytoma, but evidence is observational.

This is a retrospective audit review from a tertiary care center in eastern India, focusing on outcomes for 46 patients with solitary plasmacytoma treated with local radiotherapy. The authors synthesized data on median overall survival (OS), progression-free survival (PFS), and time to next treatment (TTNT).

The key findings are a median PFS of 9.22 years (95% CI: 5.8-12.6) and a median TTNT of 9.86 years (95% CI: 6.8-12.9). Median OS was not reached during the study. The median follow-up was 5.4 years (95% CI: 1.8-9.0).

The authors note that adverse events, serious adverse events, discontinuations, and tolerability were not reported. The study is limited by its retrospective, single-center design and lack of a comparator group.

Practice relevance is not specified. The observational nature of the audit means causal conclusions about radiotherapy efficacy cannot be drawn. The findings may inform local practice but require validation in prospective studies.

Why bone pain needs attention

Solitary plasmacytoma is a rare type of blood cancer. It grows in one spot, usually inside a bone. Most people find out they have it because of pain. It is not common, but it happens.

The pain often starts in the spine or ribs. It can feel like a bad muscle strain at first. Many people ignore it until it gets worse. This delay can make treatment harder later on.

Doctors need to know if the pain is coming from a tumor. They use scans to see exactly where the growth is. Finding the source early helps doctors plan better care.

What doctors used to believe

Many patients feared the worst when diagnosed. They thought the cancer would move to other parts of the body quickly. This fear often caused high stress and anxiety.

But the old way of thinking is changing. We now know this disease behaves differently than other blood cancers. It often stays in one place for many years. This stability is good news for patients.

Treatment plans are getting simpler and less stressful. Doctors can focus on the specific spot that is hurting. This approach helps patients keep their daily routines.

The simple science behind the treatment

Think of your body like a busy city. Plasma cells are workers that make antibodies to fight germs. Sometimes, one worker goes rogue and builds a tumor.

Radiation acts like a targeted repair crew. It fixes the bad spot without hurting the rest of the city. This precision helps keep the body safe. It stops the bad cells from growing.

The energy from the machine targets only the tumor. Healthy cells nearby can recover after the session ends. This method protects your overall strength during care.

Understanding the survival data

Researchers looked at 46 patients over 13 years. They came from a large hospital in eastern India. Most were men in their early 50s.

The results were very encouraging for those treated with radiation. Most patients did not need more treatment for nearly 10 years. This is a long time to feel well.

Some patients lived even longer without the cancer coming back. The study showed that the disease stayed under control for most people. This means daily life can continue normally.

This does not mean every patient will have the same result.

How this fits the bigger picture

Experts say this confirms what we hoped to see. It shows local treatment can work well for specific cases. It gives hope to those facing this diagnosis.

Quality of life is just as important as survival. Patients can often work and travel without major limits. This study supports using less aggressive treatments when possible.

We want to make sure patients feel good after care. Long-term control allows people to plan for their future. It reduces the need for constant hospital visits.

Your next steps with a doctor

You should talk to your doctor about your specific case. This study helps guide decisions, but it is not a rule for everyone. Every body is different.

Ask about all your treatment options before starting. A second opinion can help you feel more confident. Trust your medical team to find the best path.

Do not hesitate to ask about side effects. Knowing what to expect helps you prepare mentally. You are the most important part of the team.

Why we need more proof

The group was small and from one place. We need more data from other countries to be sure. Results might vary in different hospitals.

Small studies can sometimes miss rare side effects. Larger groups help us see the full picture clearly. We must be careful before making big changes.

Science moves slowly to ensure safety for everyone. Rushing could lead to problems we do not see yet. Patience is key to finding the best answers.

More studies will check if this works for everyone. Approval takes time to ensure safety for all patients. We wait for more evidence to confirm the path.

Scientists will look for better ways to treat the disease. They want to make sure treatments are safe for all ages. This work continues to improve care for everyone.

Study Details

Sample sizen = 46
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Introduction: Solitary plasmacytomas (SP) are rare neoplasm of localised proliferation of clonal plasma cells. It can be classified based on site of involvement and bone marrow involvement. It is an indolent disease in the majority of patients. Primary modality of treatment is radiotherapy and surgical excision. Materials and methods: This was a retrospective audit of SP who were treated and followed up at a tertiary care center in eastern India from January 2012 to December 2025. Patients who has solitary plasma cytoma with more than 10% plasma cells, POEMS syndrome, have been excluded from analysis. Results: We identified 46 patients of SP. The median age of the studied population was 53 years (23-75 years). Males were more commonly affected than females (M:F=2.2:1). Most common chief complaints were bony pain (67.4%). SBP was seen in 39 (84.8%) cases whereas SEP was seen in 7 (15.2%) cases. Vertebra was the most common site of involvement (61.4%). Median M band concentration 0.24 g/dL (0.1 to 1.95 gm/dL). IgG was the most common isotype accounting for 60.6% cases. Six cases (13%) had minimal bone marrow involvement. The majority of the patients received local radiotherapy (89.1%). With a median follow up of 5.4 years (95% CI: 1.8 - 9.0), median OS was not reached, median PFS was 9.22 years (95% CI: 5.8-12.6), median time to next treatment (TTNT) was 9.86 years (95% CI: 6.8 - 12.9). Conclusion: Solitary plasmacytoma commonly affects young males. Bones are more commonly affected than extramedullary sites. SP has a lower rate of progression and excellent prognosis when treated with local radiotherapy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.